Private and public partners unite to combat 10 neglected tropical diseases by 2020
30 January 2012 | By
Partners pledge innovative, coordinated action aimed at new WHO goals...
List view / Grid view
News
Novartis extends commitment to help achieve final elimination of leprosy
30 January 2012 | By Novartis
Novartis is a part of an international effort to eliminate or control 10 NTDs by the end of the decade...
FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adult patients with type 2 diabetes
30 January 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who…
Biogen Idec appoints Kenneth DiPietro Executive Vice President Human Resources
30 January 2012 | By Biogen Idec
Kenneth DiPietro named Executive Vice President, Human Resources...
Sanofi commits to eliminate or control five neglected tropical diseases
30 January 2012 | By Sanofi
These commitments are a key part of the "Uniting to Combat Neglected Tropical Diseases" partnership...
FDA approves Erivedge (vismodegib) capsule
30 January 2012 | By
The first medicine for adults with advanced basal cell carcinoma...
GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020
30 January 2012 | By GlaxoSmithKline
“United effort to free future generations from the burden of neglected tropical diseases..."
DNDi and Abbott expand partnership to boost innovation for neglected tropical diseases
30 January 2012 | By Abbott
DNDi & Abbott have signed a four-year joint research & non-exclusive licensing agreement...
Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash
27 January 2012 | By Roche
Roche has commenced a cash tender offer to acquire all outstanding shares of Illumina, Inc....
Pfizer announces FDA acceptance of New Drug Application for Bosutinib
27 January 2012 | By Pfizer
The U.S. FDA has accepted its NDA for standard review of bosutinib...
U.S. Food and Drug Administration approves Pfizer’s INLYTA® (axitinib)
27 January 2012 | By Pfizer
First treatment to demonstrate superior benefit in a Phase 3 study compared with another targeted agent in advanced RCC...
GSK announces changes to the Board
27 January 2012 | By GlaxoSmithKline
GlaxoSmithKline plc announced that Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board...
Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*
26 January 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced the initiation of two phase III clinical trials...
Syrris custom reactors – built for you
26 January 2012 | By Syrris
Syrris Custom Reactor Systems are ideally suited to processes requiring large reactor vessels...
Roche responds to adoption of shareholder rights plan by Illumina Board of Directors
26 January 2012 | By Roche
Roche has responded to an announcement from Illumina, Inc...
